Avita Medical Inc Stock Price, News & Analysis

AVITA Medical (NASDAQ: RCEL) announced the presentation of 16 abstracts at the American Burn Association (ABA) 2025 Annual Meeting in Phoenix, showcasing data across their wound care portfolio including RECELL®, Cohealyx™, and PermeaDerm®.

Key findings include:

• Pre-clinical study on Cohealyx showing support for wound bed vascularization within 7 days
• Largest real-world analysis of over 6,000 RECELL-treated patients demonstrating increasing adoption and consistent clinical utility
• New clinical data on PermeaDerm as an effective temporary wound coverage solution
• Randomized multicenter trial results showing PermeaDerm reduces dressing change frequency and supports early wound healing

The company aims to address the needs of over 450,000 Americans requiring medical treatment for burn injuries annually, focusing on earlier wound closure and reduced procedural complexity.

AVITA Medical (NASDAQ: RCEL) has launched Cohealyx™, a collagen-based dermal matrix co-developed with Regenity Biosciences, expanding its therapeutic wound care portfolio. The product is designed to facilitate cellular migration and revascularization for wound bed preparation, with integrated wound bed formation observed as early as 7 days in initial testing.

Cohealyx complements AVITA's existing products - the RECELL® System (FDA-approved for thermal burns and full-thickness skin defects) and PermeaDerm® (a temporary biosynthetic dressing). This integrated approach supports the two-stage standard of care for full-thickness wounds.

The company is currently conducting the Cohealyx I trial, a post-market study evaluating clinical outcomes and wound bed preparation effectiveness. Pre-clinical studies showed faster graft-ready results compared to leading competitors, potentially leading to shorter hospital stays.

AVITA Medical (NASDAQ: RCEL) has announced new strategic agreements with Stedical Scientific for PermeaDerm® Biosynthetic Wound Matrix. The company will now manufacture PermeaDerm at its Ventura, California facility under a new Contract Manufacturing Agreement effective March 17, 2025.

Key changes include:

• AVITA Medical will now retain 60% of average sales price (up from 50%) after deducting manufacturing costs
• Stedical will receive 40% of sales price (down from 50%)
• The agreement includes new performance-based milestones and extended contract terms

PermeaDerm, an FDA-cleared biosynthetic matrix for wound healing, is reimbursable across U.S. inpatient and outpatient settings. It can be used with AVITA's RECELL® devices and Spray-On Skin™ Cells for various wound types.

AVITA Medical (NASDAQ: RCEL), a therapeutic acute wound care company, has announced its upcoming participation in TD Cowen's 45th Annual Health Care Conference. Jim Corbett, the company's Chief Executive Officer, is scheduled to present on Tuesday, March 4, 2025, at 11:50 a.m. Eastern Time.

The presentation will be accessible through a live audio webcast on the Events & Presentations section of AVITA Medical's investor relations website. Interested parties can access the webcast at https://ir.avitamedical.com, and a replay will be made available after the event concludes.

AVITA Medical (NASDAQ: RCEL, ASX: AVH), a therapeutic acute wound care company, has announced an upcoming investor webinar briefing scheduled for February 18, 2025, at 2:00 p.m. Pacific Standard Time (February 19, 2025, at 9:00 a.m. Australian Eastern Daylight Time).

The presentation will be led by CEO Jim Corbett and CFO David O'Toole, focusing on the company's financial and business results from their recent fourth quarter and full-year 2024 earnings webcast. The event will include a Q&A session, with participants able to submit questions through the registration page.

Interested shareholders and prospective investors can register for the webinar via a provided Zoom link. A replay of the presentation will be made available on the AVITA Medical investor relations website.

AVITA Medical (NASDAQ: RCEL) reported its Q4 and full-year 2024 financial results. Q4 commercial revenue reached $18.4 million, up 30% year-over-year, with an 87.6% gross profit margin. Full-year 2024 revenue was $64.0 million, increasing 29% from 2023, with an 85.8% gross margin.

Key developments include FDA clearance for Cohealyx™ and RECELL GO® mini in December 2024. The company provided 2025 revenue guidance of $100-106 million, projecting 55-65% growth. AVITA expects to generate free cash flow in H2 2025 and achieve GAAP profitability in Q4 2025.

Q4 net loss was $11.6 million ($0.44 per share), compared to $7.1 million loss in Q4 2023. Full-year 2024 net loss increased to $61.8 million ($2.39 per share). The company ended 2024 with $35.9 million in cash and equivalents.

AVITA Medical (NASDAQ: RCEL) has revised its Q4 2024 commercial revenue expectations to approximately $18.4 million, representing 30% growth year-over-year, down from the previously guided $22.3-24.3 million range. Full-year 2024 revenue is now expected at $64.3 million, up 29% from 2023 but below the earlier guidance of $68-70 million.

The revenue shortfall is primarily attributed to slower purchasing activity, with hospital accounts adjusting year-end inventory levels more significantly than anticipated. The company expects normal purchasing to resume in Q1 2025, including deferred Q4 purchases.

Despite the revision, AVITA Medical maintains a positive outlook, projecting 2025 revenue between $100-106 million, representing 55-65% growth. The company has updated its timeline for achieving cashflow break-even and GAAP profitability to Q4 2025, delayed from Q3 2025. Key growth drivers include the recent launches of PermeaDerm®, RECELL GO™, RECELL GO mini, and Cohealyx™.

AVITA Medical (NASDAQ: RCEL) has received FDA approval for RECELL GO mini, a new disposable cartridge designed for treating smaller wounds up to 480 square centimeters, compared to the standard RECELL GO's 1,920 square centimeters capacity. The device, part of the RECELL GO platform, uses the same multi-use processing device but features a modified cartridge optimized for smaller skin samples, reducing resource use and minimizing waste.

This approval addresses a critical need in the full-thickness skin defect market, particularly targeting high-volume smaller wounds. The company plans to begin rollout in trauma and burn centers during Q1 2025, aiming to provide an entry point for clinicians who may not have previously used the RECELL GO platform for smaller wounds.

AVITA Medical (NASDAQ: RCEL) has received FDA 510(k) clearance for Cohealyx, a collagen-based dermal matrix co-developed with Regenity Biosciences. The product is designed for tissue integration and revascularization in full-thickness wound treatment. Preclinical studies showed Cohealyx generated robust tissue supporting skin grafts faster than leading competitors.

This strategic addition complements AVITA's existing RECELL and PermeaDerm portfolio, expected to triple the company's addressable market in burns. The company plans to initiate clinical studies in early 2025 and launch full commercialization efforts in Q2 2025.